Vioxx: an unequal partnership between safety and efficacy

@article{Lancet2004VioxxAU,
  title={Vioxx: an unequal partnership between safety and efficacy},
  author={The Lancet},
  journal={The Lancet},
  year={2004},
  volume={364},
  pages={1287-1288}
}
  • T. Lancet
  • Published 15 October 2004
  • Medicine
  • The Lancet
15 Citations
Pharmacovigilance as a Tool for Ensuring Economic Security in the Russian Healthcare System
–The article shows the role of the pharmacovigilance system for ensuring the economic security of the state by preventing and minimizing adverse reactions (ADRs) and side effects arising from the use
Post-marketing withdrawal of analgesic medications because of adverse drug reactions: a systematic review
TLDR
Greater co-ordination across regulatory authorities in assessing and interpreting the benefit-harm balance of new analgesics should be encouraged and future reporting of harms in clinical trials of analgesic should follow standardized guidelines.
Celecoxib for the Treatment of Pain in Osteoarthritis and Rheumatoid Arthritis
TLDR
The search did not identify a recent SR but did identify five RCTs that presented results on the efficacy/effectiveness of celecoxib for the treatment of patients with OA and the safety of cele Coxib for patients with RA and OA, published since July 2002.
Policy Issues for the Development and Use of Biomarkers in Health
TLDR
The report presents several policy options which could foster biomarker research, discovery, development, commercialisation and uptake in clinics and identifies the barriers which may slow or block the uptake and diffusion of biomarker-based technologies in the clinical setting.
Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials.
TLDR
There was no significant difference in the rate of MACEs observed in patients receiving anti-IL-12/IL-23 antibodies or anti-TNF-α treatments in adults, and this study may have been underpowered to identify a significant difference.
The financial and market impact of catastrophic product failure
On September 30th of 2004, Merck & Co. Inc. made the rather surprising announcement that it was withdrawing Vioxx due to its increased cardiovascular risk. The withdrawal of Vioxx was surely a
Increased risk of myocardial infarction as first manifestation of ischaemic heart disease and nonselective nonsteroidal anti-inflammatory drugs.
TLDR
Like selective COX-2 inhibitors, non-selective NSAIDs [corrected] are associated with an increased risk of MI and the extent to which this reflects interference with aspirin warrants further investigation.
Prescribers and drug withdrawals
The much publicised withdrawal of rofecoxib and the subsequent queries about the safety of celecoxib evoked a huge response in both the lay and the medical press.
Utilisation of Non-steroidal Anti-inflammatory Drugs (NSAIDs) through Community Pharmacies in Malaysia
TLDR
Elderly respondents were more likely to be dispensed a selective COX-2 inhibitor than those below 60 and NSAIDs were recommended based mainly on the pharmacist's perception of their efficacy, cost and safety.
...
...